# US 2004/0082039 A1 · Artificial proteins with reduced immunogenicity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082039 A1
- Document ID: US20040082039A1
- Status: Published application
- Kind: A1
- Application number: 10/468,370
- Filed: 2003-08-19
- Published: 2004-04-29
- Earliest claimed: 2001-02-19
- Assignees: Merck Patent GmbH
- Inventors: Stephen Gillies; Francis J Carr; Jones Tim; Graham Carter; Anita Hamilton; Stephen Williams; Marian Hanlon; John P Watkins; Matthew Baker; Jeffrey C Way
- Web page: https://patentgrep.com/patent/US20040082039A1

## CPC

- C07K 16/30: from tumour cells
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fe portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.

## Claims

### Claim 1

An immunogenicly modified fusion protein derived from a parent fusion protein, essentially consisting of a first protein/polypeptide and a second protein/polypeptide, wherein the first protein is an immunoglobulin molecule or a fragment thereof and the second protein/polypetide is non-immunoglobulin target polypeptide (X) each linked to the other directly or by a linker molecule; said modified fusion protein having an amino acid sequence different from that of said parent fusion protein and exhibiting reduced immunogenicity by a reduced number of T-cell epitopes within its amino acid sequence relative to the parent fusion protein when exposed to the immune system of a given species.

### Claim 2 (depends on 1)

A modified fusion protein according to claim 1, wherein said T-cell epitopes are peptide sequences able to bind to MCH class II molecule binding groups.

### Claim 3 (depends on 1, 2)

A modified fusion protein of claim 1 or 2, wherein the target polypeptide (X) is linked by its N-terminal to the C-terminal of the immunoglobulin moiety.

### Claim 4 (depends on 1, 2, 3)

A modified fusion protein according to any of the claims 1-3, wherein the given species is a human.

### Claim 5 (depends on 1, 2, 3)

A modified fusion protein according to any of the claims 1-3, wherein the fusion components are fused via a linker molecule L.

### Claim 6 (depends on 4)

A modified fusion protein according to claim 4, wherein said linker molecule L is non-immunogenic or less immunogenic.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A modified fusion protein according to any of the claims 1-6, wherein the fusion region represented the C-terminal region of the immunoglobulin portion and the N-terminal region of the non-immunoglobulin target polypeptide (X) has no a reduced number of T-cell epitopes.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A modified fusion protein according to any of the claims 1-7, wherein the immunoglobulin portion or a fragment thereof is less immunogenic.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

A modified fusion protein according to any of the claims 1-7, wherein the target polypeptide (X) portion is less immunogenic.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A modified fusion protein according to any of the claims 1-9, wherein said immunoglobulin molecule or fragment thereof is IgG1 or IgG2.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A modified fusion protein according to any of the claims 1-10, wherein said immunoglobulin fragment is a Fc portion.

### Claim 12 (depends on 11)

A modified fusion protein according to claim 11, wherein said Fc portion has a reduced affinity to Fc receptors.

### Claim 13 (depends on 11, 12)

A modified fusion protein according to claim 11 or 12 having the formula
Fc-Ln-X
wherein
Fc is the Fc portion of an immunoglobulin molecule (antibody),
X is a non-immunoglobulin target polypeptide
L is a linker peptide,
n=0 or 1, and
wherein X and/or L comprises amino acid residue modifications which elicit a reduced immunogenicity compared to the parent molecule.

### Claim 14 (depends on 13)

A modified fusion protein according to claim 13, wherein at least X has no a reduced immunogenicity.

### Claim 15 (depends on 14)

A modified molecule according to claim 14, wherein furthermore the fusion region between Fc and X and optionally Fc and L and/or L and X has no or a reduced number of T-cell epitopes.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A modified fusion protein according to any of the claims 1-10 having the formula
A-Ln-X
wherein
A is a whole antibody or its sFv, Fab, Fab′, F(ab′)2 fragments
X is a non-immunoglobulin target polypeptide
L is a linker peptide,
n=0 or 1, and
wherein A and/or X and/or L comprise amino acid residue modifications which elicit a reduced immunogenicity compared to the parent molecule.

### Claim 17 (depends on 16)

A modified fusion protein according to claim 16, wherein at least A or X has no or a reduced number of T-cell epitopes.

### Claim 18 (depends on 17)

A modified molecule according to claim 17, wherein furthermore the fusion region between A and X and optionally A and L and/or L and X has no or a reduced immunogenicity.

### Claim 19 (depends on 16, 17, 18)

A modified fusion protein according to any of the claims 16-18, wherein A is selected from the group:
anti-EGF receptor (HER1) antibodies
anti-HER2 antibodies
anti-CDx antibodies
anti-cytokine receptor antibodies
anti-17-1A antibodies,
anti-KSA antibodies
anti-GP IIb/IIa antibodies
anti-integrin receptor antibodies
anti VEGF receptor antibodies.

### Claim 20 (depends on 19)

A modified fusion protein according to claim 19, wherein the antibody is selected from the group:
monoclonal antibody 225 and derivatives,
monoclonal antibody 425 and derivatives
monoclonal antibody KS 1/4 and derivatives
monoclonal antibody 14.18 and derivatives
monoclonal antibody 4D5/HER2 (Herceptin®) and derivatives
monoclonal antibody 17-1A and derivatives
monoclonal antibody 7E3 and derivatives
monoclonal antibodies LM609, P1F6 and 14D9.F8 and derivatives
monoclonal antibody DC-101 and derivatives
monoclonal anti-Il-2R antibody (Zenapax®) and derivatives

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A modified fusion protein according to any of the claims 1-20, wherein the target polypeptide X is selected from the group:
cytokines, integrin inhibitors, soluble cytokine receptors, glycoproteins, hormones, glycoprotein hormones, leptin, growth hormones, growth factors, anti-hemophilic factors, antigens, cytokine receptor antagonists.

### Claim 22 (depends on 21)

A modified fusion protein according to claim 21, wherein the target polypeptide X is selected from the group:
IL-2, G-CSF, GM-CSF, EPO, TPO, TNFα, soluble TNF receptor, IL-12, IL-8, FGF, TGF, EGF, VEGF, PMSA, IGF, insulin, hGH, RGD-peptides, endostatin, angiostatin, BDNF, CNTF, protein c, factor IX, and
and biologically active fragments thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A modified fusion protein according to any of the claims 1-22, selected from the group:
MAb KS 1/4-IL2, MAb 14.18-IL2
MAb 425-IL2, MAb c425-IL2, MAb h425-IL2, MAb 425-TNFa
MAb 225-IL2, MAb c225-IL2
MAb 4D5-1-2, MAb DC101-112, MAb LM609-IL2,
Fc-IL2, Fc-TNFa, Fc-G-CSF, Fc-EPO, Fc-Leptin, Fc-KGF,
Fc-BDNF, Fc-CNTF, FC-B-Cerebrosidase, Fc-TPO, Fc-GM-CSF,

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 36)

A DNA sequence encoding a fusion protein of any of the claims 1-23 and 36.

### Claim 25 (depends on 24)

A DNA sequence of claim 24, comprising
(i) a signal sequence
(ii) a DNA sequence encoding all domains or a Fc, sFV, Fab, Fab′ or F(ab′)2 domain of an IgG1, IgG2 or IgG3 antibody, and
(ii) a DNA sequence encoding the polypeptide (X), and optionally
(iii) a DNA sequence encoding the linker molecule.

### Claim 26 (depends on 24, 25)

An expression vector comprising a DNA sequence of claims 24 or 25.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 36)

A pharmaceutical composition comprising a fusion protein according any of the claims 1-23 and 36, optionally together with a suitable carrier, excipient or diluent.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method for preparing an immunogenicly modified fusion protein as specified in of the claims 1-23 comprising the steps:
(i) determining the amino acid sequence of the parent fusion protein or part thereof;
(ii) identifying one or more potential T-cell epitopes within the amino acid sequence of the fusion protein by any method including determination of the binding of the peptides to MHC molecules using in vitro or in silico techniques or biological assays, (iii) designing new sequence variants by alteration of at least one amino acid residue within the originally identified T-cell epitope sequences, said variants are modified in such a way to substantially reduce or eliminate the activity or number of the T-cell epitope sequences and/or the number of MHC allotypes able to bind peptides derived from said biological molecule as determined by the binding of the peptides to MHC molecules using in vitro or in silico techniques or biological assays or by binding of peptide-MHC complexes to T-cells, (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties, and (v) optionally repeating steps (ii)-(iv),
characterized in that the identification of T-cell epitope sequences according to step (ii) is achieved by
(a) selecting a region of the peptide having a known amino acid residue sequence;
(b) sequentially sampling overlapping amino acid residue segments of predetermined uniform size and constituted by at least three amino acid residues from the selected region; (c) calculating MHC Class II molecule binding score for each said sampled segment by summing assigned values for each hydrophobic amino acid residue side chain present in said sampled amino acid residue segment; and (d) identifying at least one of said segments suitable for modification, based on the calculated MHC Class II molecule binding score for that segment, to change overall MHC Class II binding score for the peptide without substantially the reducing therapeutic utility of the peptide.

### Claim 29 (depends on 28)

The method according to claim 28, wherein step (c) is carried out by using a Böhm scoring function modified to include 12-6 van der Waal's ligand-protein energy repulsive term and ligand conformational energy term by (1) providing a first data base of MHC Class II molecule models; (2) providing a second data base of allowed peptide backbones for said MHC Class II molecule models; (3) selecting a model from said first data base; (4) selecting an allowed peptide backbone from said second data base; (5) identifying amino acid residue side chains present in each sampled segment; (6) determining the binding affinity value for all side chains present in each sampled segment; and optionally (7) repeating steps (1) through (5) for each said model and each said backbone.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the sampled amino acid residue segment is constituted by 13 amino acid residues.

### Claim 31 (depends on 28, 29, 30)

The method of any of the claims 28-30, wherein consecutive sampled amino acid residue segments overlap by one to five amino acid residues.

### Claim 32 (depends on 28, 29, 30, 31)

The method of any of the claims 28-31, wherein 1-9 amino acid residues in any of the originally present T-cell epitope sequences are altered.

### Claim 33 (depends on 32)

The method according to claim 32, wherein one amino acid residue in any of the originally present T-cell epitope sequences is altered.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein the alteration of the amino acid residues is substitution, deletion or addition of originally present amino acid(s) residue(s) by other amino acid residue(s) at specific position(s).

### Claim 35 (depends on 34)

The method of claims 34, wherein additionally further alteration by substitution, deletion or addition is conducted to restore biological activity of said biological molecule.

### Claim 36 (depends on 28, 29, 30, 31, 32, 33, 34, 35)

An immunogenicly modified artificial protein selected from the group:
(i) Y-(L)-X, wherein Y is a cytokine and X, (L) is a molecule as defined above,
(ii) P-(L)-X, wherein P is a protein with unusual glycosylation moieties and X, (L) is a molecule as defined above,
(iii) A-(L)-X, wherein A is an immunoglobulin or a fragment thereof and X (L) is a molecule as defined above,
derived from a parent artificial protein having an amino acid sequence which is different from that of said parent artificial protein and exhibits reduced immunogenicity by a reduced number of T-cell epitopes relative to the parent fusion protein when exposed to the immune system of a given species, wherein said T-cell epitopes are peptide sequences able to bind to MCH class II molecule binding groups obtainable by a method as specified in any of the claims 28-35.

### Claim 37 (depends on 36)

An artificial protein of claim 36, wherein at least A or X or Y or P is immunogenicly modified.
